Sign in
4

Changes in Ownership

Trevi Therapeutics, Inc. Filed Acc 0001209191-23-052687

Chief Financial Officer sold 785 shares at $2.02 ($1,586)

  • Chief Financial Officer acquired 2,292 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Delfini Lisa · Chief Financial Officer

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2023-10-11 Exercise or conversion : show line 1 in the form 10b5-1 +2,292 $0.51 $1,171 36,686 D
2023-10-11 Sale : show line 2 in the form 10b5-1 −785 $2.02 $1,586 35,901 D
Open-market sales · 785 sh · avg $2.02 · $1,586

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2023-10-11 Exercise or conversion : show line 3 in the form 10b5-1 Stock Option (right to buy) −2,292 64,168 D
Loading xslF345X05/doc4.xml…